The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CONTACT-2: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
 
Neeraj Agarwal
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Exelixis; Pfizer
 
Arun Azad
Honoraria - Aculeus Therapeutics; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar
Consulting or Advisory Role - Aculeus Therapeutics; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Novartis
Research Funding - Aptevo Therapeutics (Inst); Astellas Pharma; Astellas Pharma (Inst); AstraZeneca; AstraZeneca (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hinova Pharmaceuticals (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); Merck Serono; Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Synthorx (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Janssen; Merck Serono; Pfizer; Sanofi; Tolmar
 
Joan Carles
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; Astellas Pharma; AstraZéneca; Bayer; Bristol-Myers Squibb; Johnson & Johnson/Janssen; MSD Oncology; Pfizer; Roche; Sanofi
Speakers' Bureau - Astellas Pharma; Bayer; Johnson & Johnson
Research Funding - AB Science (Inst); Aragon Pharmaceuticals (Inst); Arog (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Blueprint Medicines (Inst); BN ImmunoTherapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb International Corporation (BMS) (Inst); Clovis Oncology (Inst); Cougar Biotechnology (Inst); Deciphera; Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen-Cilag International NV (Inst); Karyopharm Therapeutics (Inst); Laboratories Leurquin Mediolanum (Inst); Lilly (Inst); Medimmune (Inst); Millenium Pharamceuticals (Inst); Nanobiotix (Inst); Novartis Farmacéutica SA (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Sanofi Aventis GmbH (Inst); SFJ Pharmaceuticals Group (Inst); Teva (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BMS; Ipsen; Roche
Other Relationship - Catalan Program of Ambulatory Medication Comission (CAHMDA)
 
Nobuaki Matsubara
Honoraria - Sanofi
Consulting or Advisory Role - Amgen; AstraZeneca; Janssen; Lilly; Pfizer; Sanofi; Seagen
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer Yakuhin (Inst); Chugai Pharma (Inst); Eisai (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Roche/Genentech (Inst); Seagen (Inst); Takeda (Inst)
 
Stephane Oudard
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; IPSEN,; Janssen; Merck; MSD; Novartis; Pfizer; Sanofi
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; IPSEN,; Janssen; Merck; MSD; Novartis; Pfizer; Roche; Sanofi
 
Fred Saad
Honoraria - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bayer; BMS; Janssen Oncology; Knight Therapeutics; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi
Consulting or Advisory Role - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Janssen Oncology; Knight Therapeutics; Myovant Sciences; Novartis; Pfizer; Sanofi
Research Funding - Advanced Accelerator Applications (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)
 
Axel S. Merseburger
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Janssen-Cilag; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Clovis Oncology; Ipsen; Janssen-Cilag; MSD Oncology; Takeda
Speakers' Bureau - Ipsen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Janssen-Cilag (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Ipsen; Janssen-Cilag
 
Andrey Soares
Honoraria - Adium Pharma; Astellas Pharma; AstraZeneca; Bayer; IPSEN,; Janssen; Merck Serono; Pfizer; Sanofi
Consulting or Advisory Role - Adium Pharma; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; IPSEN,; Janssen; MSD; Roche
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Adium Pharma; Bayer; IPSEN,; Janssen; MSD
 
Bradley Alexander McGregor
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Genentech/Roche; Merck; Pfizer; Seattle Genetics/Astellas
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Pfizer/EMD Serono (Inst); Seattle Genetics/Astellas (Inst)
 
Bogdan Zurawski
Employment - Bristol-Myers Squibb/Roche; GlaxoSmithKline; Janssen Oncology; Merck Serono; MSD Oncology; Novartis
Honoraria - Astellas Pharma; Roche
 
Scott A. North
Honoraria - Exelixis; Roche
Research Funding - Exelixis (Inst)
 
Marinos Tsiatas
Honoraria - AstraZeneca; Bayer; GlaxoSmithKline; IPSEN,; Janssen; Merck; MSD; Pfizer
Consulting or Advisory Role - Astellas Pharma; Bayer; IPSEN,; Janssen; Merck; MSD; Novartis
Research Funding - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Exelixis; Gilead Sciences; Janssen; Merck; MSD; Pfizer
Travel, Accommodations, Expenses - AstraZeneca; IPSEN,; Janssen; MSD; Pfizer
 
Igor Bondarenko
No Relationships to Disclose
 
Margarita Sonia Alfie
No Relationships to Disclose
 
Lena Evilevitch
Employment - Exelixis
Stock and Other Ownership Interests - Exelixis
 
Keerti Sharma
Employment - Exelixis
 
Prachi Nandoskar
Employment - Exelixis
Stock and Other Ownership Interests - Bristol-Myers Squibb; Exelixis
 
Roberta Ferraldeschi
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Fong Wang
Employment - Exelixis; Medivation
Stock and Other Ownership Interests - Exelixis; Medivation
Research Funding - Exelixis; Medivation
Travel, Accommodations, Expenses - Exelixis; Exelixis; Medivation
 
Sumanta Kumar Pal
Travel, Accommodations, Expenses - crispr therapeutics; Exelixis; Ipsen